American Century Companies Inc. Purchases New Position in XBiotech Inc. (NASDAQ:XBIT)

American Century Companies Inc. acquired a new position in shares of XBiotech Inc. (NASDAQ:XBIT) during the 2nd quarter, Holdings Channel reports. The fund acquired 76,460 shares of the biopharmaceutical company’s stock, valued at approximately $393,000.

A number of other institutional investors have also recently bought and sold shares of XBIT. Rhumbline Advisers raised its holdings in XBiotech by 2,568.5% in the second quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 19,341 shares during the period. Empowered Funds LLC increased its position in shares of XBiotech by 7.9% in the 1st quarter. Empowered Funds LLC now owns 64,277 shares of the biopharmaceutical company’s stock valued at $523,000 after buying an additional 4,725 shares in the last quarter. Bank of New York Mellon Corp raised its stake in XBiotech by 102.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 49,863 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in XBiotech by 1.6% during the first quarter. Vanguard Group Inc. now owns 895,315 shares of the biopharmaceutical company’s stock worth $7,279,000 after acquiring an additional 13,804 shares in the last quarter. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Trading Down 6.0 %

NASDAQ:XBIT opened at $7.05 on Friday. The stock has a market cap of $214.73 million, a price-to-earnings ratio of -7.11 and a beta of 1.41. The stock has a 50-day moving average price of $6.74 and a two-hundred day moving average price of $7.15. XBiotech Inc. has a 1 year low of $3.51 and a 1 year high of $9.96.

XBiotech (NASDAQ:XBIT) last issued its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.